Naoya Yamazaki

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 72

Top Topics

Combination Therapy

Basal Cell Carcinoma

Top Venues

The Journal of dermatology

Japanese journal of clinical oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Seiji Tsuruta, Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Naoya Yamazaki
A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options. Japanese journal of clinical oncology (2024)
Hisashi Uhara, Yoshio Kiyohara, Taiki Isei, Kotaro Nagase, Anzu Kambe, Masashi Sato, Yutaro Tanaka, Naoya Yamazaki
Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance. The Journal of dermatology 51 (4) (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Hisashi Uhara, Yoshio Kiyohara, Taiki Isei, Kotaro Nagase, Anzu Kambe, Masashi Sato, Yutaro Tanaka, Naoya Yamazaki
Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance. The Journal of dermatology 51 (4) (2024)
Kenjiro Namikawa, Eiji Nakano, Dai Ogata, Naoya Yamazaki
Long-term survival with systemic therapy in the last decade: Can melanoma be cured? The Journal of dermatology (2024)
Eiji Nakano, Akira Takahashi, Dai Ogata, Kenjiro Namikawa, Naoya Yamazaki
Real-world efficacy and safety of BRAF-targeted therapy for patients with advanced melanoma: A single-center retrospective study in Japan. The Journal of dermatology (2024)
Hisashi Uhara, Yoshio Kiyohara, Taiki Isei, Kotaro Nagase, Anzu Kambe, Masashi Sato, Yutaro Tanaka, Naoya Yamazaki
Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance. The Journal of dermatology (2024)
Shogo Wada, Eiji Nakano, Miho Nakajima, Satsuki Kishikawa, Akihiko Yoshida, Taisuke Mori, Atsuyoshi Osada, Dai Ogata, Kenjiro Namikawa, Naoya Yamazaki
Congenital dermatofibrosarcoma protuberans on the scalp enlarging and shrinking repeatedly. The Journal of dermatology (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Wataru Yamagami, Naoya Yamazaki, Shigenori Kadowaki, Hiroya Taniguchi, Makoto Ueno, Shogen Boku, Eiji Oki, Yoshito Komatsu, Satoshi Yuki, Akitaka Makiyama, Tomoyuki Otsuka, Hiroki Hara, Naohiro Okano, Tomohiro Nishina, Yasutoshi Sakamoto, Izumi Miki, Shin Kobayashi, Junichiro Yuda, Shun-Ichiro Kageyama, Michiko Nagamine, Shingo Sakashita, Naoya Sakamoto, Riu Yamashita, Yoshikatsu Koga, Hideaki Bando, Genichiro Ishii, Takeshi Kuwata, Woong-Yang Park, Atsushi Ohtsu, Takayuki Yoshino
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer discovery (2024)
Yusuke Muto, Taku Fujimura, Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Shunichi Jinnai, Akira Hashimoto, Yumi Kanbayashi, Yoshihide Asano, Naoya Yamazaki
Analysis of surgical margins and prognostic factors in dermatofibrosarcoma protuberans after wide local excision: A multicenter study of 116 Japanese patients. The Journal of dermatology 51 (9) (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Kenjiro Namikawa, Eiji Nakano, Dai Ogata, Naoya Yamazaki
Long-term survival with systemic therapy in the last decade: Can melanoma be cured? The Journal of dermatology 51 (3) (2024)
Yusuke Muto, Taku Fujimura, Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Shunichi Jinnai, Akira Hashimoto, Yumi Kanbayashi, Yoshihide Asano, Naoya Yamazaki
Analysis of surgical margins and prognostic factors in dermatofibrosarcoma protuberans after wide local excision: A multicenter study of 116 Japanese patients. The Journal of dermatology (2024)
Eiji Nakano, Akira Takahashi, Dai Ogata, Kenjiro Namikawa, Naoya Yamazaki
Real-world efficacy and safety of BRAF-targeted therapy for patients with advanced melanoma: A single-center retrospective study in Japan. The Journal of dermatology 51 (9) (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Shogo Wada, Eiji Nakano, Miho Nakajima, Satsuki Kishikawa, Akihiko Yoshida, Taisuke Mori, Atsuyoshi Osada, Dai Ogata, Kenjiro Namikawa, Naoya Yamazaki
Congenital dermatofibrosarcoma protuberans on the scalp enlarging and shrinking repeatedly. The Journal of dermatology 51 (6) (2024)
Akemi Fukuda, Dai Ogata, Yoichi Oshima, Eiji Nakano, Kenjiro Namikawa, Motoaki Komatsu, Akira Nakamura, Kohei Sugiura, Naoya Yamazaki
Grade 3 acute kidney injury caused anti-glomerular basement membrane nephritis during immune checkpoint inhibitor treatment for melanoma. The Journal of dermatology (2024)
Kenjiro Namikawa, Eiji Nakano, Dai Ogata, Naoya Yamazaki
Long-term survival with systemic therapy in the last decade: Can melanoma be cured? The Journal of dermatology 51 (3) (2024)
Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Maiko Fujimori, Yosuke Uchitomi, Takahiro Higashi, Naoya Yamazaki, Akira Kawai
Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017. Cancer science (2023)
Shogo Wada, Dai Ogata, Eiji Nakano, Kenjiro Namikawa, Naoya Yamazaki
Efficacy of chemotherapies for unresectable extramammary Paget disease: a single-centre retrospective study. Clinical and experimental dermatology (2023)
Paolo Antonio Ascierto, Reinhard Dummer, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T Flaherty
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF -Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Eiji Nakano, Dai Ogata, Kenjiro Namikawa, Naoya Yamazaki
Merkel cell carcinoma: a review of clinical management with focus on Asian patients. Japanese journal of clinical oncology (2023)
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, James M G Larkin, Georgina V Long, Rachel E Sanborn, Vanna Chiarion Sileni, Brigitte Dreno, Stéphane Dalle, Dirk Schadendorf, Margaret K Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez Roca, Naoya Yamazaki, Hussein A Tawbi, Naomey Sarkis, Deepti M Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Go Omura, Kenjiro Namikawa, Toshihiko Sakai, Kohtaro Eguchi, Yoshifumi Matsumoto, Azusa Sakai, Kenya Kobayashi, Eiji Nakano, Dai Ogata, Fumihiko Matsumoto, Taisuke Mori, Naoya Yamazaki, Seiichi Yoshimoto
Clinical outcomes of head and neck mucosal melanoma treated with surgery: a single-center study in Japan. Japanese journal of clinical oncology (2023)
Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Tetsuya Tsuchida, Ai Yoshida, Takako Yamada, Akira Komoto
Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma. The Journal of dermatology (2023)
Shogo Wada, Tomone Watanabe, Taisuke Ishii, Yuichi Ichinose, Ryoko Rikitake, Dai Ogata, Eiji Nakano, Kenjiro Namikawa, Naoya Yamazaki, Takahiro Higashi
A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use. Cancer medicine (2023)
Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Maiko Fujimori, Yosuke Uchitomi, Takahiro Higashi, Naoya Yamazaki, Akira Kawai
Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017. Cancer science (2023)
Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Maiko Fujimori, Yosuke Uchitomi, Takahiro Higashi, Naoya Yamazaki, Akira Kawai
Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017. Cancer science (2023)
Yuichi Nakayama, Dai Ogata, Shogo Wada, Seiji Tsuruta, Yoshiyuki Matsui, Mao Okumura, Kojiro Hiki, Eiji Nakano, Kenjiro Namikawa, Naoya Yamazaki
Treatment of high tumor mutation burden metastatic extramammary Paget disease with an anti-PD-1 antibody. The Journal of dermatology (2023)
Naoya Yamazaki, Akiko Shimizu, Masahiko Ozaki, Masahiro Hamada, Noriko Takeuchi, Yuichiro Ito, Shinichiroh Maekawa
Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all-case postmarketing surveillance in Japan. The Journal of dermatology 49 (11) (2022)
Mao Okumura, Dai Ogata, Kenjiro Namikawa, Keita Tsutsui, Akira Takahashi, Kae Okuma, Tairo Kashihara, Hiroshi Igaki, Masashi Akiyama, Naoya Yamazaki
Postoperative radiation therapy improves prognoses in extramammary Paget's disease presenting with multiple lymph node metastases. The Journal of dermatology 49 (10) (2022)
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer science (2022)
Naoya Yamazaki, Taiki Isei, Yoshio Kiyohara, Hiroshi Koga, Takashi Kojima, Tatsuya Takenouchi, Kenji Yokota, Kenjiro Namikawa, Min Yi, Alissa Keegan, Satoshi Fukushima
A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Cancer science 113 (8) (2022)
Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana M Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo Antonio Ascierto
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Anna Kamimura, Yasuhiro Nakamura, Tatsuya Takenouchi, Shigeto Matsushita, Toshikazu Omodaka, Kentaro Yamamura, Hiroshi Uchi, Shusuke Yoshikawa, Hiroto Yanagisawa, Takamichi Ito, Yoshio Kiyohara, Yoshio Nakamura, Megumi Aoki, Shoichiro Ishizuki, Kohei Oashi, Takuya Miyagawa, Taku Maeda, Dai Ogata, Naohito Hatta, Shuichi Ohe, Taiki Isei, Akira Takahashi, Yoshiyasu Umeda, Buntaro Yamaguchi, Masashi Ishikawa, Kohei Horimoto, Yasuhiro Fujisawa, Jiro Uehara, Yoshitsugu Shibayama, Yukiko Kiniwa, Yu Kawahara, Taisuke Matsuya, Hisashi Uhara, Junji Kato, Yoshiyuki Nakamura, Takuo Murakami, Kenjiro Namikawa, Koji Yoshino, Takeru Funakoshi, Sumiko Takatsuka, Yu Matsui, Jin Sasaki, Hiroshi Koga, Kenji Yokota, Takaya Komori, Satoshi Fukushima, Naoya Yamazaki
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN). The Journal of dermatology 49 (9) (2022)
Hisashi Uhara, Tetsuya Tsuchida, Yoshio Kiyohara, Ayumi Akamatsu, Takahiko Sakamoto, Naoya Yamazaki
Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance. The Journal of dermatology 49 (9) (2022)
Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Shunichi Jinnai, Eiji Nakano, Naoya Yamazaki
Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. The Journal of dermatology (2022)
Yuichiro Ohe, Naoya Yamazaki, Nobuyuki Yamamoto, Haruyasu Murakami, Kiyotaka Yoh, Shigehisa Kitano, Hideyuki Hashimoto, Ayako Murayama, Sayuri Nakane, Akihiko Gemma
The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. Japanese journal of clinical oncology 52 (6) (2022)
Kojiro Hiki, Dai Ogata, Izumi Hisada, Taku Sakamoto, Takamaru Hiroyuki, Kohei Yamakawa, Kenjiro Namikawa, Akira Takahashi, Yutaka Saito, Naoya Yamazaki
Minimally invasive surgery combined with excision and endoscopic submucosal dissection for anorectal melanoma. The Journal of dermatology (2022)
Akihiro Ishiguro, Dai Ogata, Kae Okuma, Tairo Kashihara, Naoya Murakami, Kojiro Hiki, Kohei Yamakawa, Shunichi Jinnai, Akira Takahashi, Kenjiro Namikawa, Hiroshi Igaki, Naoya Yamazaki
Malignant melanoma treatment using brachytherapy: Two case reports and 15 case series. The Journal of dermatology (2022)
Mao Okumura, Eiji Nakano, Kenjiro Namikawa, Akira Takahashi, Yutaka Fujiwara, Naoya Yamazaki
Efficacy of surgery for skin cancers initially suspected to be carcinoma of unknown primary: a retrospective observational study. International journal of dermatology (2021)
Hisashi Uhara, Yoshio Kiyohara, Jiro Uehara, Yasuhiro Fujisawa, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Satoshi Fukushima, Hironobu Minami, Masahiro Hatsumichi, Naoya Yamazaki
Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. The Journal of dermatology 48 (5) (2021)
Akihiro Ishiguro, Dai Ogata, Kenjiro Namikawa, Akira Takahashi, Naoya Yamazaki
Two cases of advanced cutaneous squamous cell carcinoma lesions on the head and neck successfully treated with nivolumab. The Journal of dermatology 48 (9) (2021)
Keita Tsutsui, Katsuko Kikuchi, Keiko Nozawa, Atsuo Takashima, Kenichiro Tsuchiyama, Kenjiro Namikawa, Setsuya Aiba, Naoya Yamazaki
Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial. The Journal of dermatology 48 (7) (2021)
Erina Takai, Wataru Omata, Yasushi Totoki, Hiromi Nakamura, Satoshi Shiba, Akira Takahashi, Kenjiro Namikawa, Taisuke Mori, Naoya Yamazaki, Tatsuhiro Shibata, Hirotsugu Shiroma
Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Cancer science 112 (11) (2021)
Kenta Nakama, Dai Ogata, Eiji Nakano, Keita Tsutsui, Shunichi Jinnai, Kenjiro Namikawa, Akira Takahashi, Naoya Yamazaki
Clinical response to a MEK inhibitor in a patient with metastatic melanoma harboring an RAF1 gene rearrangement detected by cancer gene panel testing. The Journal of dermatology 48 (6) (2021)
Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Shunichi Jinnai, Kenta Nakama, Keita Tsutsui, Yusuke Muto, Haruki Mizuta, Naoya Yamazaki
Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. The Journal of dermatology 47 (11) (2020)
Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Tetsuya Tsuchida, Keiko Maruyama, Naoki Shakunaga, Eijun Itakura, Akira Komoto
Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance. The Journal of dermatology 47 (8) (2020)
Moeka Kawada, Yoshimasa Nobeyama, Yasushi Goto, Kenta Nakama, Naoya Yamazaki, Akihiko Asahina
Absence of toxic epidermal necrolysis recurrence with pembrolizumab re-challenge in a patient with a positive lymphocyte transformation test. The Journal of dermatology 47 (12) (2020)
Keita Tsutsui, Akira Takahashi, Taisuke Mori, Kenjiro Namikawa, Naoya Yamazaki
Secretory carcinoma of the skin arising on the eyelid, distinguished by immunohistochemical markers and fluorescence in situ hybridization. The Journal of dermatology 47 (3) (2020)
Eiji Nakano, Akira Takahashi, Kenjiro Namikawa, Yusuke Muto, Shunichi Jinnai, Yuta Kage, Haruki Mizuta, Arata Tsutsumida, Naoya Yamazaki
Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. The Journal of dermatology 47 (6) (2020)
Kenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, Hisashi Uhara, Hiroshi Uchi, Shusuke Yoshikawa, Sumiko Takatsuka, Hiroshi Koga, Naoko Wada, Hironobu Minami, Masahiro Hatsumichi, Yoshinobu Namba, Naoya Yamazaki
Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma. The Journal of dermatology 47 (11) (2020)
Haruki Mizuta, Eiji Nakano, Akira Takahashi, Takafumi Koyama, Kenjiro Namikawa, Naoya Yamazaki
Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. Dermatologic therapy 33 (3) (2020)
Keita Tsutsui, Kenjiro Namikawa, Taisuke Mori, Ken Kato, Shunichi Jinnai, Kenta Nakama, Dai Ogata, Akira Takahashi, Naoya Yamazaki
Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. The Journal of dermatology 48 (2) (2020)
Keita Tsutsui, Akira Takahashi, Yusuke Muto, Haruki Mizuta, Shunichi Jinnai, Kenta Nakama, Dai Ogata, Kenjiro Namikawa, Naoya Yamazaki
Outcomes of lymph node dissection in the treatment of extramammary Paget's disease: A single-institution study. The Journal of dermatology 47 (5) (2020)
Rei Watanabe, Susumu Okano, Naoya Yamazaki
Fixed drug eruption dramatically exacerbated during treatment with programmed death 1 inhibitor. The Journal of dermatology 47 (12) (2020)
Keita Tsutsui, Kenjiro Namikawa, Taisuke Mori, Shunichi Jinnai, Kenta Nakama, Dai Ogata, Akira Takahashi, Naoya Yamazaki
Case of multiple ectopic extramammary Paget's disease of the trunk. The Journal of dermatology 47 (9) (2020)
Kenji Yokota, Hiroshi Uchi, Hisashi Uhara, Shusuke Yoshikawa, Tatsuya Takenouchi, Takashi Inozume, Kentaro Ozawa, Hironobu Ihn, Yasuhiro Fujisawa, Anila Qureshi, Veerle de Pril, Yasushi Otsuka, Jeffrey Weber, Naoya Yamazaki
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study. The Journal of dermatology 46 (12) (2019)
Akira Takahashi, Kenjiro Namikawa, Eiji Nakano, Naoya Yamazaki
Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma. The Journal of dermatology 47 (3) (2019)
Yusuke Muto, Kenjiro Namikawa, Yutaka Fujiwara, Taisuke Mori, Eiji Nakano, Akira Takahashi, Naoya Yamazaki
Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report. The Journal of dermatology 47 (1) (2019)
Yusuke Muto, Shigehisa Kitano, Arata Tsutsumida, Kenjiro Namikawa, Akira Takahashi, Yoshio Nakamura, Takeharu Yamanaka, Noboru Yamamoto, Naoya Yamazaki
Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. The Journal of dermatology 46 (6) (2019)
Arata Tsutsumida, Satoshi Fukushima, Kenji Yokota, Shusuke Yoshikawa, Osamu Yamasaki, Atsushi Tanemura, Ryuhei Okuyama, Hisashi Uhara, Yusuke Muto, Azusa Miyashita, Masashi Akiyama, Tatsuya Kaji, Hiroshi Koga, Junji Kato, Teruaki Katayama, Eijun Itakura, Naoya Yamazaki, Yoshio Kiyohara
Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma. The Journal of dermatology 46 (11) (2019)
Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Jiro Uehara, Yasuhiro Fujisawa, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Hironobu Ihn, Masahiro Hatsumichi, Hironobu Minami
Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. Cancer science 110 (6) (2019)
Shiro Kimbara, Yutaka Fujiwara, Shintaro Iwama, Ken Ohashi, Aya Kuchiba, Hiroshi Arima, Naoya Yamazaki, Shigehisa Kitano, Noboru Yamamoto, Yuichiro Ohe
Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer science 109 (11) (2018)
Yoshio Kiyohara, Hisashi Uhara, Yoshihiko Ito, Noritake Matsumoto, Tetsuya Tsuchida, Naoya Yamazaki
Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. The Journal of dermatology 45 (4) (2018)
Katsuko Kikuchi, Keiko Nozawa, Naoya Yamazaki, Yasuo Nakai, Ayaka Higashiyama, Masayuki Asano, Yutaka Fujiwara, Shintaro Kanda, Yuichiro Ohe, Atsuo Takashima, Narikazu Boku, Akira Inoue, Masanobu Takahashi, Takahiro Mori, Osamu Taguchi, Yasuhiro Inoue, Hitoshi Mizutani
Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. The Journal of dermatology 46 (1) (2018)
Rei Watanabe, Eiji Nakano, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Kouhei Shitara, Akira Takahashi, Arata Tsutsumida, Aya Nishizawa, Naoya Yamazaki
Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab. The Journal of dermatology 46 (5) (2018)
Naoya Yamazaki, Arata Tsutsumida, Akira Takahashi, Kenjiro Namikawa, Shusuke Yoshikawa, Yutaka Fujiwara, Shunsuke Kondo, Akihira Mukaiyama, Fanghong Zhang, Yoshio Kiyohara
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma. The Journal of dermatology 45 (4) (2018)
Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Hajime Iizuka, Jiro Uehara, Fujio Otsuka, Yasuhiro Fujisawa, Tatsuya Takenouchi, Taiki Isei, Keiji Iwatsuki, Hiroshi Uchi, Hironobu Ihn, Hironobu Minami, Hideaki Tahara
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer science 108 (5) (2017)
Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Jiro Uehara, Manabu Fujimoto, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Hironobu Ihn, Hironobu Minami
Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. Cancer science 108 (6) (2017)
Masayuki Tsuneki, Takao Kinjo, Taisuke Mori, Akihiko Yoshida, Kayo Kuyama, Aoi Ohira, Takuya Miyagi, Kenzo Takahashi, Akira Kawai, Hirokazu Chuman, Naoya Yamazaki, Mikio Masuzawa, Hirofumi Arakawa
Survivin: A novel marker and potential therapeutic target for human angiosarcoma. Cancer science 108 (11) (2017)